News Headlines Article

New tests for choosing right hep C drug could save money
Washington Post

New tests designed to help doctors pick the right hepatitis C medicine for patients could mean faster cures and lower costs.

Quest Diagnostics Inc.’s latest two tests can predict whether two recently approved medicines — Zepatier and Daklinza —will fight a patient’s specific type of hepatitis C or whether the liver-destroying virus likely would “resist” them. Several months ago, Quest had launched other tests to help doctors decide if four older medicines would suit patients.

There are six hepatitis C “genotypes,” plus some subtypes, and now six approved medicines that each treat one or more of those types.